Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Mol Neurobiol ; 55(1): 335-349, 2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-28856531

RESUMEN

A comparative study performed in mice investigating the action of DF302, a novel fluoride-containing gamma-carboline derivative, in comparison to the structurally similar neuroprotective drug dimebon. Drug effects on learning and memory, emotionality, hippocampal neurogenesis and mitochondrial functions, as well as AMPA-mediated currents and the 5-HT6 receptor are reported. In the step-down avoidance and fear-conditioning paradigms, bolus administration of drugs at doses of 10 or 40 mg/kg showed that only the higher dose of DF302 improved long-term memory while dimebon was ineffective at either dosage. Short-term memory and fear extinction remained unaltered across treatment groups. During the 5-day predation stress paradigm, oral drug treatment over a period of 2 weeks at the higher dosage regimen decreased anxiety-like behaviour. Both compounds supressed inter-male aggression in CD1 mice, the most eminent being the effects of DF302 in its highest dose. DF302 at the higher dose decreased floating behaviour in a 2-day swim test and after 21-day ultrasound stress. The density of Ki67-positive cells, a marker of adult neurogenesis, was reduced in the dentate gyrus of stressed dimebon-treated and non-treated mice, but not in DF302-treated mice. Non-stressed mice that received DF302 had a higher density of Ki67-positive cells than controls unlike dimebon-treated mice. Similar to dimebon, DF302 effectively potentiated AMPA receptor-mediated currents, bound to the 5-HT6 receptor, inhibited mitochondrial permeability transition and displayed cytoprotective properties in cellular models of neurodegeneration. Thus, DF302 exerts multi-target effects on the key mechanisms of neurodegenerative pathologies and can be considered as an optimized novel analogue of the neuroprotective agent dimebon.


Asunto(s)
Carbolinas/administración & dosificación , Sistemas de Liberación de Medicamentos/métodos , Compuestos de Flúor/administración & dosificación , Memoria/efectos de los fármacos , Neurogénesis/efectos de los fármacos , Estrés Psicológico/tratamiento farmacológico , Animales , Compuestos de Flúor/metabolismo , Indoles/administración & dosificación , Indoles/química , Masculino , Memoria/fisiología , Ratones , Ratones Endogámicos C57BL , Neurogénesis/fisiología , Ratas , Receptores de Serotonina/metabolismo , Estrés Psicológico/metabolismo , Estrés Psicológico/psicología
2.
Behav Brain Res ; 335: 122-127, 2017 09 29.
Artículo en Inglés | MEDLINE | ID: mdl-28803855

RESUMEN

Glycogen synthase kinase 3 (GSK3) has been linked to the mechanisms of stress, mood regulation, and the effects of antidepressants. The functions of the GSK3ß isoform have been extensively investigated, but little is known about the α-isoform, although they may functionally related. In a recently established modified swim test with a third delayed swim exposure, brain GSK3ß mRNA expression positively correlated with floating behaviour on the third test. A two-week-long pretreatment regime with imipramine (7.5mg/kg/day) or thiamine (200mg/kg/day), which is known to have antidepressant properties, reduced the GSK3ß over-expression and decreased floating behaviour on Day 5. GSK3α mRNA levels were measured in the hippocampus and prefrontal cortex on Days 1, 2 and 5. GSK3α expression was decreased in the prefrontal cortex on Day 2 and increased on Day 5. In this model, GSK3α mRNA changes were prevented by imipramine or thiamine treatment. There was a significant correlation between the expression of the two isoforms in the prefrontal cortex on Day 2 in untreated group. These results provide the first evidence for the potential involvement of GSK3α in depressive-like behaviours and as a target of anti-depressant therapy. Furthermore, the correlations suggest some cross-talk may exist between the two GSK3 isoforms.


Asunto(s)
Antidepresivos/farmacología , Encéfalo/enzimología , Depresión/tratamiento farmacológico , Depresión/enzimología , Glucógeno Sintasa Quinasa 3 beta/metabolismo , Glucógeno Sintasa Quinasa 3/metabolismo , Animales , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Encéfalo/patología , Depresión/metabolismo , Depresión/patología , Modelos Animales de Enfermedad , Imipramina/farmacología , Masculino , Ratones , Ratones Endogámicos C57BL , Fosforilación , Isoformas de Proteínas , Transducción de Señal/efectos de los fármacos , Tiamina/farmacología , Regulación hacia Arriba
3.
Neural Plast ; 2017: 9498247, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28685102

RESUMEN

Nonalcoholic fatty liver disease, induced by a Western diet (WD), evokes central and peripheral inflammation that is accompanied by altered emotionality. These changes can be associated with abnormalities in social behaviour, hippocampus-dependent cognitive functions, and metabolism. Female C57BL/6J mice were fed with a regular chow or with a WD containing 0.2% of cholesterol and 21% of saturated fat for three weeks. WD-treated mice exhibited increased social avoidance, crawl-over and digging behaviours, decreased body-body contacts, and hyperlocomotion. The WD-fed group also displayed deficits in hippocampal-dependent performance such as contextual memory in a fear conditioning and pellet displacement paradigms. A reduction in glucose tolerance and elevated levels of serum cholesterol and leptin were also associated with the WD. The peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1a) mRNA, a marker of mitochondrial activity, was decreased in the prefrontal cortex, hippocampus, hypothalamus, and dorsal raphe, suggesting suppressed brain mitochondrial functions, but not in the liver. This is the first report to show that a WD can profoundly suppress social interactions and induce dominant-like behaviours in naïve adult mice. The spectrum of behaviours that were found to be induced are reminiscent of symptoms associated with autism, and, if paralleled in humans, suggest that a WD might exacerbate autism spectrum disorder.


Asunto(s)
Trastorno Autístico/etiología , Conducta Animal/fisiología , Dieta Occidental/efectos adversos , Trastornos de la Memoria/etiología , Animales , Trastorno Autístico/metabolismo , Encéfalo/metabolismo , Femenino , Ratones , Coactivador 1-alfa del Receptor Activado por Proliferadores de Peroxisomas gamma/metabolismo
4.
Artículo en Inglés | MEDLINE | ID: mdl-27825907

RESUMEN

Thiamine (vitamin B1) deficiency in the brain has been implicated in the development of dementia and symptoms of depression. Indirect evidence suggests that thiamine may contribute to these pathologies by controlling the activities of glycogen synthase kinase (GSK)-3ß. While decreased GSK-3ß activity appears to impair memory, increased GSK-3ß activity is associated with the distressed/depressed state. However, hitherto direct evidence for the effects of thiamine on GSK-3ß function has not been reported. Here, we administered thiamine or, the more bioavailable precursor, benfotiamine at 200mg/kg/day for 2weeks to C57BL/6J mice, to determine whether treatment might affect behaviours that are known to be sensitive to GSK-3ß activity and whether such administration impacts on GSK-3ß expression within the brain. The mice were tested in models of contextual conditioning and extinction, a 5-day rat exposure stress test, and a modified swim test with repeated testing. The tricyclic antidepressant imipramine (7.5mg/kg/day), was administered as a positive control for the effects of thiamine or benfotiamine. As for imipramine, both compounds inhibited the upregulation of GSK-3ß induced by predator stress or repeated swimming, and reduced floating scores and the predator stress-induced behavioural changes in anxiety and exploration. Coincident, thiamine and benfotiamine improved learning and extinction of contextual fear, and the acquisition of the step-down avoidance task. Our data indicate that thiamine and benfotiamine have antidepressant/anti-stress effects in naïve animals that are associated with reduced GSK-3ß expression and conditioning of adverse memories. Thus thiamine and benfotiamine may modulate GSK-3ß functions in a manner that is dependent on whether the contextual conditioning is adaptive or maladaptive.


Asunto(s)
Trastornos del Conocimiento/tratamiento farmacológico , Glucógeno Sintasa Quinasa 3 beta/metabolismo , Estrés Psicológico , Tiamina/análogos & derivados , Tiamina/uso terapéutico , Complejo Vitamínico B/uso terapéutico , Animales , Reacción de Prevención/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/enzimología , Trastornos del Conocimiento/etiología , Trastornos del Conocimiento/patología , Condicionamiento Psicológico/efectos de los fármacos , Modelos Animales de Enfermedad , Extinción Psicológica/efectos de los fármacos , Miedo/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Glucógeno Sintasa Quinasa 3 beta/genética , Masculino , Ratones , Ratones Endogámicos C57BL , ARN Mensajero/metabolismo , Estrés Psicológico/complicaciones , Estrés Psicológico/tratamiento farmacológico , Estrés Psicológico/metabolismo , Natación/psicología , Tiamina/farmacología , Factores de Tiempo
5.
Neural Plast ; 2016: 5098591, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27478647

RESUMEN

While deficient brain plasticity is a well-established pathophysiologic feature of depression, little is known about disorder-associated enhanced cognitive processing. Here, we studied a novel mouse paradigm that potentially models augmented learning of adverse memories during development of a depressive-like state. We used a modification of the classic two-day protocol of a mouse Porsolt test with an additional session occurring on Day 5 following the initial exposure. Unexpectedly, floating behaviour and brain glycogen synthase kinase-3 beta (GSK-3beta) mRNA levels, a factor of synaptic plasticity as well as a marker of distress and depression, were increased during the additional swimming session that was prevented by imipramine. Observed increases of GSK-3beta mRNA in prefrontal cortex during delayed testing session correlated with individual parameters of behavioural despair that was not found in the classic Porsolt test. Repeated swim exposure was accompanied by a lower pGSK-3beta/GSK-3beta ratio. A replacement of the second or the final swim sessions with exposure to the context of testing resulted in increased GSK-3beta mRNA level similar to the effects of swimming, while exclusion of the second testing prevented these changes. Together, our findings implicate the activation of brain GSK-3beta expression in enhanced contextual conditioning of adverse memories, which is associated with an individual susceptibility to a depressive syndrome.


Asunto(s)
Encéfalo/enzimología , Depresión/enzimología , Glucógeno Sintasa Quinasa 3 beta/biosíntesis , Individualidad , Natación , Animales , Depresión/genética , Depresión/psicología , Expresión Génica , Glucógeno Sintasa Quinasa 3 beta/genética , Masculino , Ratones , Ratones Endogámicos C57BL , Valor Predictivo de las Pruebas , Estrés Psicológico/enzimología , Estrés Psicológico/genética , Estrés Psicológico/psicología , Natación/psicología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA